Cite

HARVARD Citation

    Okamoto, T. et al. (n.d.). Anti-B16 melanoma effects of a STAT3 inhibitor (rR9-GRIM19) are strongly enhanced by co-treatment with recombinant interferons. Journal of dermatological science. 84 (1), pp. e84-e85. [Online]. 
  
Back to record